Pseudo hyperparathyroidism describes a clinical scenario where biochemical markers mimic primary hyperparathyroidism, yet the underlying pathology lies outside the parathyroid glands. This condition is characterized by elevated serum calcium and suppressed parathyroid hormone (PTH) levels, creating a diagnostic paradox. Unlike the primary form, which originates from a parathyroid adenoma or hyperplasia, the pseudo variant is secondary to an external source of calcitriol or calcium intake. Recognizing this distinction is critical for clinicians to avoid inappropriate parathyroid surgery and to target the true etiology effectively.
Mechanisms of Calcium Dysregulation
The fundamental mechanism behind pseudo hyperparathyroidism involves unregulated increases in calcitriol, the active form of vitamin D. This surplus enhances intestinal absorption of calcium, leading to hypercalcemia. In response, the body's feedback loop appropriately downregulates PTH secretion, resulting in inappropriately low or undetectable PTH levels for the degree of hypercalcemia. This differs fundamentally from primary hyperparathyroidism, where high calcium should trigger low PTH, but the gland ignores the signal. Consequently, the calcium-PTH axis is disrupted, pointing to a parathyroid-independent cause.
Granulomatous Diseases and Extrarenal Production
The most common culprits are granulomatous diseases, such as sarcoidosis and tuberculosis. Within these granulomas, activated macrophages express the enzyme 1-alpha-hydroxylase, which converts 25-hydroxyvitamin D to calcitriol independently of normal regulatory controls. This pathological overproduction drives excessive calcium absorption. Other conditions, like lymphoma, can also ectopically produce calcitriol. Additionally, exogenous intake of calcitriol supplements, often prescribed for osteoporosis or renal bone disease, can overwhelm the system if not carefully monitored, leading to iatrogenic pseudo hyperparathyroidism.
Clinical Presentation and Diagnostic Challenges
Patients frequently present with symptoms of hypercalcemia, including polyuria, polydipsia, constipation, nausea, and profound fatigue. However, the symptom profile can be subtle or attributed to the underlying granulomatous illness, leading to a delay in diagnosis. The diagnostic workup hinges on interpreting the calcium and PTH relationship. A hypercalcemic state with a low or inappropriately normal PTH level immediately shifts the differential away from primary hyperparathyroidism. Further investigation focuses on identifying the source of calcitriol overproduction.
Serum Calcium: Elevated, often in the moderate range.
Parathyroid Hormone (PTH): Low or inappropriately normal.
1,25-Dihydroxyvitamin D (Calcitriol): Elevated, which is the hallmark finding.
Phosphorus: Variable, but often normal or low.
Differentiating from Primary Hyperparathyroidism
Distinguishing pseudo from primary hyperparathyroidism is essential to prevent unnecessary parathyroidectomy. The key differentiator is the PTH level in the context of hypercalcemia. In primary hyperparathyroidism, PTH is inappropriately high or normal. In the pseudo variant, PTH is suppressed. Measuring calcitriol is equally crucial; an elevated level strongly supports a granulomatous or extrarenal source, while a low level might point toward exogenous vitamin D intake or rare genetic disorders. A thorough medication and supplement history is therefore indispensable.
